- BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer
- Combination study pairing KEYTRUDA with Bria-IMT is ongoing, with initial efficacy data for the first six patients to be released at AACR Annual Meeting
- BriaCell has closed the first tranche of a previously announced non-brokered private placement, raising gross proceeds of C$750,000
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, will present an analysis of the initial efficacy data compiled during a combination study that pairs Bria-IMT, the company’s lead cellular immunotherapy candidate, with pembrolizumab (KEYTRUDA, manufactured by Merck & Co. Inc.) in advanced breast cancer. Data is now being finalized and will be shared via press release and in conjunction with BriaCell’s poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia, on April 3 (http://ibn.fm/w8UEd).
“The early efficacy data of the first six patients in our Phase I/IIa study of Bria-IMT with KEYTRUDA represents an important milestone for BriaCell as a rapidly advancing company with an innovative technology,” Dr. Bill Williams, BriaCell’s president and CEO, stated in a news release. “Through the combination study, we are learning more about the mechanism of action of our novel immunotherapy, which will aid in assessment of combining Bria-IMT with other drugs, including other checkpoint inhibitors.”
BriaCell’s focus on the development of targeted immunotherapy solutions for advanced breast cancer patients has, to date, demonstrated excellent results with Bria-IMT in several clinical trials. More than 2.1 million new cases of breast cancer were documented globally in 2018, according to the Cancer Research Institute, with medical advances still lagging for treatment of advanced breast cancer patients (http://ibn.fm/jAZmB). BriaCell has already achieved proof of concept with Bria-IMT in clinical trials in advanced breast cancer, showing an outstanding safety profile, as well as excellent efficacy, as an earlier article details (http://ibn.fm/7PAV3).
BriaCell’s combination study with KEYTRUDA, which began in October 2018 and is ongoing, primarily measures synergistic effects of the combination on tumor regression and biological response. Together, Bria-IMT and KEYTRUDA, are expected to show that the combined action of the two may be greater than the sum of their individual effects in “awakening” the immune system of the patient, as the company stated in a news release.
An additional C$750,000 has been raised following the closure of the first tranche of BriaCell’s previously-announced non-brokered private placement. BriaCell intends to use the net proceeds from the offering to finance its phase IIa combination study of Bria-IMT with KEYTRUDA in advanced breast cancer; to finance its pursuit of other research opportunities; and for working capital and general corporate purposes, per a news release (http://ibn.fm/Zq7Wp).
For more information, visit the company’s website at www.BriaCell.com
NOTE TO INVESTORS: The latest news and updates relating to BCTXF are available in the company’s newsroom at http://ibn.fm/BCTXF
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.